Last Updated: May 12, 2026

Suppliers and packagers for NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE


✉ Email this page to a colleague

« Back to Dashboard


NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Altaire Pharms Inc NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE naphazoline hydrochloride; pheniramine maleate SOLUTION/DROPS;OPHTHALMIC 078208 ANDA Altaire Pharmaceuticals Inc. 59390-177-13 15 mL in 1 BOTTLE, DROPPER (59390-177-13) 2010-10-06
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

Last updated: May 10, 2026

Who Supplies Naphazoline Hydrochloride and Pheniramine Maleate for Pharmaceutical Use?

What are the commercially relevant supplier categories for these APIs?

Supplies for Naphazoline Hydrochloride and Pheniramine Maleate typically flow through four procurement channels, each with distinct documentation and quality expectations:

Supplier channel What it supplies Typical buyer use case
API manufacturers Active pharmaceutical ingredient (API) in bulk Commercial API procurement, contract manufacturing input
API importers/distributors API sourced from an upstream maker, sold under own distribution controls Faster sourcing, reduced qualification burden vs direct maker
Contract manufacturers (CDMOs) Finished intermediates and finished dosage forms, plus API as needed Outsourced development and manufacturing
Specialty chemical suppliers Lab/technical grade and sometimes pharma-grade via documentation Early formulation work, method development, limited QA expectations

For either API, buyers generally need: CEP/DMF (if available), CoA, GMP certificate for the manufacturing site, and product-specific impurity specs aligned to the intended market.


Which suppliers manufacture or distribute Naphazoline Hydrochloride (API)?

The supplier universe for Naphazoline Hydrochloride is dominated by API manufacturers in Asia and Europe, plus distributors that carry pharma-grade inventory. Procurement lists typically include:

  • API manufacturers producing naphazoline hydrochloride under cGMP/HEP (where applicable) with export documentation
  • Pharma distributors that sell under a controlled distribution model and can supply CoA batches on request

However, no verifiable supplier roster can be stated from the information provided. A complete, accurate “supplier list” requires sourcing the names from authoritative registries (for example, drug master files, CEP certificate holders, or FDA/EMA facility listings) or from authenticated procurement databases. This request does not include any registry snapshot, geography, grade (pharma vs technical), or documentation constraints, so enumerating specific company names would be incomplete or potentially incorrect.


Which suppliers manufacture or distribute Pheniramine Maleate (API)?

Pheniramine Maleate has a similarly structured supply chain: multiple API makers worldwide and a parallel layer of distributors and contract manufacturing networks.

  • API manufacturers supplying pharma-grade bulk material
  • Distributors sourcing from one or more upstream manufacturers and providing batch-level documentation

As with naphazoline hydrochloride, a complete and accurate supplier list cannot be produced from the provided input.


What procurement documentation typically distinguishes pharma-grade API supply from technical-grade supply?

Buyers usually screen supplier quality using the following artifacts and controls:

Documentation item Why it matters
GMP certificate for API site Confirms regulated manufacturing environment
CEP (EDQM) or DMF reference Demonstrates regulatory dossier alignment
CoA with batch-specific impurity profile Validates specification compliance
Transport and handling controls Minimizes degradation and mix-ups
Analytical methods and impurity list Ensures reproducible quality and regulatory defensibility

Even where supplier names are available, these artifacts determine whether the material can enter a controlled pharmaceutical manufacturing chain.


What finished product context matters for these APIs?

These APIs commonly appear in combination ophthalmic or decongestant formulations (depending on market), and that context affects which supplier routes are used:

  • Ophthalmic / nasal decongestant formulations often require tighter impurity and particle specs at the API and finished product level.
  • Combination products increase traceability requirements because APIs must match the finished formulation pathway used by the MAH.

That means not all “API suppliers” qualify equally for the buyer’s intended dosage form and market authorization strategy.


Key Takeaways

  • Supply for Naphazoline Hydrochloride and Pheniramine Maleate typically comes from API manufacturers and pharma-grade distributors, with CDMOs involved when the buyer outsources formulation and manufacturing.
  • A specific named supplier roster cannot be produced accurately from the provided input because it requires authoritative source confirmation (GMP/CEP/DMF or verified procurement databases).
  • Procurement readiness depends more on documentation and spec alignment (GMP certificate, CEP/DMF, CoA, impurity profile) than on marketing claims.

FAQs

  1. Are naphazoline hydrochloride and pheniramine maleate sold as APIs only, or also as intermediates?
    They are primarily procured as APIs for drug manufacture; some supply chains also involve intermediate synthesis for internal production by API makers.

  2. Do CDMOs always source these APIs, or can they require the MAH to supply them?
    CDMOs typically can supply APIs if qualified, but many contracts allow or require customer-supplied APIs under agreed quality agreements.

  3. What is the most important qualification document for API suppliers?
    A current GMP certificate for the specific manufacturing site is the gating item in most pharma procurement frameworks.

  4. Can a distributor be used instead of an API manufacturer directly?
    Yes, when the distributor can provide full batch traceability, CoA, and confirm the upstream manufacturing site’s regulatory status.

  5. Does intended dosage form change API supplier requirements?
    Yes. Ophthalmic or other sensitive dosage forms often drive stricter impurity, particle, and control strategy requirements.


References

[1] European Directorate for the Quality of Medicines & HealthCare (EDQM). European Certificates of Suitability (CEPs) database.
[2] FDA. Drug Master Files (DMF) database and related guidance (FDA access and listing pages).
[3] EMA. EudraGMDP and related GMP inspection and manufacturer information resources.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.